| Literature DB >> 16972997 |
Javid A Dar1, Manzoor A Thoker, Jamal A Khan, Asif Ali, Mohammed A Khan, Mohammed Rizwan, Khalid H Bhat, Mohammad J Dar, Niyaz Ahmed, Shamim Ahmad.
Abstract
BACKGROUND: The study was conducted between 2000 and 2003 on 750 human subjects, yielding 850 strains of staphylococci from clinical specimens (575), nasal cultures of hospitalized patients (100) and eye & nasal sources of hospital workers (50 & 125 respectively) in order to determine their epidemiology, acquisition and dissemination of resistance genes.Entities:
Mesh:
Year: 2006 PMID: 16972997 PMCID: PMC1592298 DOI: 10.1186/1476-0711-5-22
Source DB: PubMed Journal: Ann Clin Microbiol Antimicrob ISSN: 1476-0711 Impact factor: 3.944
Antibiotic resistance profiles of 61 strains of MRSA isolated in an orthopaedic surgical ward
| 1. | A,Cz,Ce,Cp,Co,G,I,M,P,R,Ro,T | 12 | JMR-1 |
| 2. | Ak,A,Cz,Ce,Cp,Cf,Cd,Co,G,I,M,P,Ro | 13 | JMR-2 |
| 3. | Ak,A,Cz,Ce,Cp,Co,G,I,M,P,Ro | 11 | JMR-3, 55, 33, 59 |
| 4. | A,Cz,Ce,Cp,Cd,Co,G,I,M,P,T | 11 | JMR-4 |
| 5. | A,Cz,Ce,Cp,Cd,Co,G,M,P | 9 | JMR-5 |
| 6. | A,Cz,Ce,Cp,Cf,Cd,Co,G,M,P,R,Ro | 12 | JMR-6, 38, 51 |
| 7. | A,Cz,Ce,Cp,Cf,Co,M,P,R,Ro | 10 | JMR-7 |
| 8. | Ce,Cd,Co,M,P,R | 6 | JMR-8 |
| 9. | A,Cz,Ce,Cp,C,Cd,Co,M,P,R | 10 | JMR-9 |
| 10. | Ak,A,Cz,Ce,Cp,Cf,Co,G,M,P,R,Ro,T | 13 | JMR-10 |
| 11. | Ak,A,Cz,Ce,Cp,Cd,Co,G,M,P,R,Ro | 12 | JMR-11, 53 |
| 12. | Ak,A,Cz,Ce,Cf,Cd,Co,G,I,M,P,R,Ro | 13 | JMR-12 |
| 13. | A,Cz,Ce,Cp,Cd,Co,G,M,P,R | 10 | JMR-13 |
| 14. | A,Cz,Ce,Cp,Co,M,P,R | 8 | JMR-14 |
| 15. | A,Cz,Ce,Cp,Cf,Co,G,M,P,R | 10 | JMR-15, 58 |
| 16. | A,Cz,Ce,Cp,Cf,Co,G,M,P | 9 | JMR-16 |
| 17. | Ak,A,Cz,Ce,Cp,Cd,Co,G,M,P,R | 11 | JMR-17 |
| 18. | A,Cz,Ce,Cp,Co,G,M,P,R | 9 | JMR-18 |
| 19. | Ak,A,Cz,Ce,Cp,Co,G,M,P,Ro | 10 | JMR-19, 61 |
| 20. | Ak,A,Cz,Ce,Cp,Cd,Co,G,I,M,P,R,Ro | 13 | JMR-20 |
| 21. | A,Ce,Cp,C,Co,G,M,P,T | 9 | JMR-21 |
| 22. | Ak,A,Cz,Cp,Co,G,I,M,P,Ro,T | 11 | JMR-22 |
| 23. | A,Cz,Ce,Cp,Co,G,M,P,Ro | 9 | JMR-23 |
| 24. | Ak,A,Cz,Ce,Cp,Cf,Cd,Co,G,M,P,Ro,T | 13 | JMR-24, 46, 48, 39 |
| 25. | Ak,A,Cz,Ce,Cp,C,Cf,Co,Fc,G,I,M,R,Ro,T | 15 | JMR-25 |
| 26. | A,Cz,Ce,Cp,Co,G,M,P,Ro,T | 10 | JMR-26, 52 |
| 27. | A,Cz,Ce,Cp,Co,G,M,P,Ro,T | 10 | JMR-27 |
| 28. | Ak,A,Cz,Ce,Cp,C,Cf,Cd,Co,Fc,G,I,M,P,R,Ro,T | 17 | JMR-28, 60 |
| 29 | A,Cz,Ce,Cp,C,Cd,Co,G,M,P,R,Ro,T | 13 | JMR-29 |
| 30. | A,Cz,Ce,Cp,Co,G,I,M,P,R,Ro | 11 | JMR-30 |
| 31. | Ce,Cp,Cd,Co,M,P | 6 | JMR-31, 56 |
| 32. | A,Cz,Ce,Cp,Cf,Co,G,M,P,R,Ro,T | 12 | JMR-32 |
| 33. | A,Cz,Ce,Cp,C,Cf,Cd,G,Co,I,M,P,Ro,T | 14 | JMR-34 |
| 34. | A,Cz,Ce,Cp,C,Co,G,M,P,Ro,T | 11 | JMR-35 |
| 35. | Ak,A,Cz,Ce,Cp,C,Co,G,M,P,R,Ro | 12 | JMR-36, 49 |
| 36. | Cz,Ce,Cp,Cd,Co,M,P | 7 | JMR-37, 45, 50, 54 |
| 37. | A,Cz,Ce,Cp,Cf,Co,M,P,R | 9 | JMR-40 |
| 38. | A,Cz,Ce,Cp,C,Cf,Cd,Co,Fc,G,I,M,P,R,Ro,T | 16 | JMR-41 |
| 39. | Ak,A,Cz,Cp,I,M,P,Ro | 8 | JMR-42 |
| 40. | A,Cz,Ce,Cp,Cd,Co,G,M,P,R,Ro | 11 | JMR-43 |
| 41. | A,Cz,Ce,Cp,Cf,Co,G,M,P,Ro | 10 | JMR-44 |
| 42. | A,Cz,Ce,Cp,Co,G,M,P,Ro | 9 | JMr-47, 57 |
Age and gender distribution of staphylococcal infected/colonized subjects (n = 750) according to clinical diagnosis
| Clinical Diagnosis n = 750 (100%) | Age (Y) | |||||||||||
| 5–14 n = 63 (%) | 15–24 n = 133 (%) | 25–44 n = 224 (%) | 45–64 n = 182 (%) | >65 n = 96 (%) | Unknowna n = 52 (%) | |||||||
| Male n = 31(49.2) | Female n = 32 (50.8) | Male n = 67(50.4) | Female n = 66(49.6) | Male n = 116(51.8) | Female n = 108(48.2) | Male n = 101(55.5) | Female n = 81(44.5) | Male n = 56(58.3) | Female n = 40(41.7) | Male n = 23(44.2) | Female n = 29(55.8) | |
| Wound infection n = 122 (16.2) | 8 (12.7) | 5 (7.9) | 16 (12.0) | 14 (10.5) | 16 (7.1) | 7 (3.1) | 17 (9.3) | 16 (8.8) | 9 (9.4) | 7 (7.3) | 2 (3.8) | 5 (9.6) |
| Postoperative infection n = 35 (4.7) | 1 (1.6) | 2 (3.2) | 2 (1.5) | 1 (0.7) | 2 (0.9) | 8 (3.6) | 4 (2.2) | 5 (2.7) | 8 (8.3) | 2 (2.1) | - | - |
| Bacteraemia n = 25 (3.3) | 1 (1.6) | 1 (1.6) | - | 2 (1.5) | 4 (1.8) | 2 (0.9) | 7 (3.8) | 4 (2.2) | 1 (1.0) | - | 2 (3.8) | 1 (1.9) |
| Pneumonia n = 21 (2.8) | 5(7.9) | 1 (1.6) | 1 (0.7) | - | 1 (0.4) | 1 (0.4) | 1 (0.5) | 2 (1.1) | 3 (3.1) | 1 (1.0) | 3 (5.8) | 2 (3.8) |
| Septicaemia n = 15 (2.0) | - | - | 1 (0.7) | 1 (0.7) | 1 (0.4) | 2 (0.9) | 2 (1.1) | 2 (1.1) | 1 (1.0) | - | 2 (3.8) | 3 (5.8) |
| Urinary tract infections n = 89 (11.9) | - | 1 (1.6) | 4 (3.0) | 5 (3.8) | 10 (4.5) | 15 (6.7) | 14 (7.7) | 15 (8.2) | 9 (9.4) | 11(11.5) | - | 5 (9.6) |
| Mastatitis n = 12 (1.6) | - | - | - | 2 (1.5) | - | 8 (3.6) | - | 2 (1.1) | - | - | - | - |
| Prostatitis n = 18 (2.4) | - | - | 1 (0.7) | - | 5 (2.2) | - | 9 (4.9) | - | 3 (3.1) | - | - | - |
| Conjunctivitis n = 52 (6.9) | 7 (11.1) | 5 (7.9) | 5 (3.8) | 4 (3.0) | 1 (0.4) | 4 (1.8) | 7 (3.8) | 5 (2.7) | 4 (4.2) | 5 (5.2) | 3 (5.8) | 2 (3.8) |
| Corneal ulcer n = 20 (2.7) | 1 (1.6) | - | 2 (1.5) | - | 2 (0.9) | 1 (0.4) | 2 (1.1) | 3 (1.6) | 3 (3.1) | 2 (2.1) | 1 (1.9) | 3 (5.8) |
| Endophthalmitis n = 11 (1.5) | - | - | 1 (0.7) | - | - | 1 (0.4) | 2 (1.1) | 2 (1.1) | 2 (2.1) | 1 (1.0) | 1 (1.9) | 1 (1.9) |
| Otherb n = 110 (14.7) | 8 (12.7) | 13 (20.6) | 11 (8.3) | 13 (9.8) | 12 (5.3) | 8 (3.6) | 12 (6.6) | 8 (4.4) | 11 (11.5) | 9 (9.4) | 3 (5.8) | 2 (3.8) |
| Normalc n = 175 (23.3) | - | - | 20 (15.0) | 18 (13.5) | 56 (25.0) | 46 (20.5) | 16 (8.8) | 15 (8.2) | - | - | 2 (3.8) | 2 (3.8) |
| Unknownd n = 45 (6.0) | - | 4 (6.3) | 3 (2.2) | 6 (4.5) | 6 (2.7) | 5 (2.2) | 8 (4.4) | 2 (1.1) | 2 (2.1) | 2 (2.1) | 4 (7.7) | 3 (5.8) |
aAge not recorded for 52 subjects.
bAbscess or osteomyelitis, cystitis, peritonitis, endocarditis, toxic shock syndrome, keratitis, etc.
cStrains isolated from nose of hospital workers attending wound infections (n=50), nose of hospital workers (n=75) and normal eyes of hospital workers (n=50) respectively in Orthopaedic Surgical Ward of J.N Medical College, A.M.U., Aligarh, S.K. Institute of Medical Sciences Kashmir and Surgical Wards of Institute of Ophthalmology, A.M.U. Aligarh.
dClinical diagnosis not recorded for 45 subjects.
Resistance profilesa of staphylococcal isolates (n = 850) from eyes and other clinical sources in health and disease
| Antimicrobial Agent (n = 18)b | Percentage of Resistancec Displayed by | |||||
| Clinical | Carrier | Coagulase-negative Staphylococci (CNS) n = 337 (%) | Clinical CNS n = 237 (%) | Carrier CNS n = 100 (%) | ||
| Amikacin | 65 (12.7) | 47 (13.9) | 18 (10.3) | 27 (8.0) | 27 (11.4) | 0 (0.0) |
| Ampicillin | 413 (80.5) | 275 (81.4) | 138 (78.8) | 241 (71.5) | 183 (77.2) | 58 (58.0) |
| Cefazolin | 190 (37.0) | 131 (38.8) | 59 (33.7) | 80 (23.7) | 64 (27.0) | 16 (16.0) |
| Cephalexin | 237 (46.2) | 165 (48.8) | 72 (41.1) | 86 (25.5) | 68 (28.7) | 18 (18.0) |
| Cephotaxime | 207 (40.3) | 145 (42.9) | 62 (35.4) | 78 (23.2) | 68 (28.7) | 16 (16.0) |
| Chloramphenicol | 22 (4.3) | 16 (4.7) | 6 (3.4) | 17 (5.0) | 12 (5.1) | 5 (5.0) |
| Ciprofloxacin | 103 (20.1) | 81 (24.0) | 22 (12.6) | 75 (22.2) | 56 (23.6) | 19 (19.0) |
| Clindamycin | 79 (15.4) | 60 (17.7) | 19 (10.9) | 71 (21.1) | 56 (23.6) | 15 (15.0) |
| Co-trimoxazoled | 256 (50.0) | 175 (51.8) | 81 (46.3) | 136 (40.3) | 104 (43.9) | 32 (32.0) |
| Fusidic acid | 18 (3.5) | 14 (4.1) | 4 (2.3) | 12 (3.6) | 8 (3.4) | 4 (4.0) |
| Gentamicin | 172 (33.5) | 122 (36.1) | 50 (28.6) | 90 (26.7) | 72 (30.4) | 18 (18.0) |
| Imipenem | 136 (26.5) | 97 (28.7) | 39 (23.3) | 68 (20.2) | 54 (22.8) | 14 (14.0) |
| Methicilline | 180 (35.1) | 128 (37.9) | 52 (29.7) | 76 (22.5) | 63 (26.6) | 13 (13.0) |
| Penicillin G | 472 (92.0) | 313 (92.6) | 159 (90.9) | 303 (89.9) | 222 (93.7) | 81 (81.0) |
| Rifampin | 97 (18.9) | 68 (20.1) | 29 (16.6) | 41 (12.2) | 33 (13.9) | 8 (8.0) |
| Roxithromycin | 146 (24.6) | 103 (30.5) | 43 (24.6) | 53 (15.7) | 48 (20.2) | 8 (8.0) |
| Tetracycline | 61 (11.9) | 43 (12.7) | 18 (10.3) | 24 (7.1) | 21 (8.9) | 3 (3.0) |
| Vancomycin | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
aIn accordance to Performance Standards for Antimicrobial Disk Susceptibility Tests, NCCLS (1998, 1999, 2000, 2002).
bAtleast one antimicrobial agent assayed from a particular class of antibiotics.
cThe intermediate resistant category was included in sensitive category.
d(trimethoprim/sulphamethoxazole).
eMethicillin resistance was confirmed by Oxacillin Salt-agar screening – plate procedure
Figure 1Distribution of staphylococcal isolates among the clinical sources. Out of 151 isolates from pus, 115 were S. aureus and 36 were coagulase-negative staphylococci (CNS). Likewise, of 153 isolates from urine, 77 were CNS and 76 were S. aureus. Of the 225 nasal swabs of hospital workers and patients studied, 175 (34.1%) were S. aureus and 50 (14.8%) were CNS.
Figure 2Occurrence of multidrug resistance in methicillin-resistant and methicillin-sensitive S. aureus clinical and carrier isolates.
Figure 3Occurrence of multidrug resistance in methicillin-resistant and methicillin-sensitive coagulase-negative staphylococcal clinical and carrier Isolates.
Figure 4Pulsed-field gel electrophoresis (PFGE) profiles of MRSA. Fourteen MRSA fingerprint patterns were identified for the 61 strains of MRSA isolated in an Orthopaedic Surgical Ward. These strains were collected from wound infections (n = 56); patient's nose (n = 50); and nose of the hospital workers attending wound infections (n = 50). Lanes 1, 9 and 17 represent S. aureus 8325 patterns for comparison. Lanes 2 to 16 barring 9 respectively represent PFGE banding patterns A to N.
PFGE patterns of 61 MRSA isolates
| A | JMR-1, 2, 3, 4, 6, 38, 55 | 7 |
| B | JMR-5, 14, 18 | 3 |
| C | JMR-9, 13, 19, 26, 52 | 5 |
| D | JMR-16, 25, 29 | 3 |
| E | JMR-24, 46, 48, 39 | 4 |
| F | JMR-31, 56 | 2 |
| G | JMR-37, 50, 54, 15, 58 | 5 |
| H | JMR-21, 40, 42, 44, 59, 61 | 6 |
| I | JMR-8 | 1 |
| J | JMR-17, 20, 23, 27, 30, 32, | 6 |
| K | JMR-11, 12, 28, 41, 53 60, | 6 |
| L | JMR-22, 33, 34, 35, 36 | 5 |
| M | JMR-43, 45, 51 | 3 |
| N | JMR-7, 10, 47, 49, 57 | 5 |
Figure 5Pulsed-field gel electrophoresis (PFGE) of MRSA clinical isolates. PFGE patterns were indistinguishable between MRSA from the nasal cavity (na) and pus (ps) but the patterns were different for MRSA from the skin (s) and nearby wounds for cases 1 and 8. PFGE patterns were indistinguishable between MRSA from the nasal cavity and pus and closely related to that of MRSA from the skin for case 2. PFGE patterns were indistinguishable between MRSA from the skin and pus but closely related to that of MRSA from the nasal cavity for case 7. The patterns of MRSA isolates from the nasal cavity, skin, and pus were indistinguishable for cases 3, 4, 5, & 6.
Figure 6Agarose gel electrophoresis of crude plasmid DNA. Lane A, MRSA, resistant to A, G and Ak, having 4.3 kb plasmid (pJMR10); Lane B, E. coli (DH5α) sensitive to A, G, and Ak; Lane C, Transformant E. coli (DH5α) having 4.3 kb plasmid; Lane D, S. aureus RN834, containing the plasmid molecular markers.
Minimal inhibitory concentrations of A, G, Ak for S. aureus strain JMR10 and one E. coli transformant
| 800 | 1000 | 200 | |
| 1 | 1 | 3 | |
| 200 | 100 | 400 | |
Figure 7Plasmids transferred in conjugation through mixed culture test (MCT) experiments (broth matings). Lane A, Carrier S. aureus, JN-49 (AR, PR, CfR, ER, GS, TS), having 2.8 kb plasmid. Lane B, Clinical S. aureus, JS-105 (TR, ER, GR, AS, PS, CfS), having 38 kb and 4.4 kb plasmid; Lane C, Cured trasnconjugant, JNS-1A (GR, ER, CfR, TS, AS, PS), having 38 kb plasmid; Lane D, Cured trasnconjugant, JNS-1B (ER, CfR, TS, GS, AS, PS), having no plasmid; Lane E, Transconjugant JNS-1 (TR, CfR, ER, GR, AR, PR), having 38 kb, 4.4 kb and 2.8 kb plasmid; Lane F, Cured Transconjugant JNS-1C (TR, CfR, ER, GS, AS, PS), having 4.4 kb plasmid; Lane G, Plasmid marker, S. aureus WBG 4483.